 There are certain mutations, such as the one you mentioned, BRCA, that are significant and really implicate specific types of treatments, like the platinums or the PARP inhibitors. But in heart cancers like glioblastoma, we see some of those same mutations, but patients don't respond. The reality is these tumors are very heterogeneous, meaning it's really not one mutation. These malignant, hard to treat tumors are not so simple. They have multiple mutations, multiple things going wrong in them, so that they evade the immune system, they just grow out of control, and they really adapt it to be very aggressive. Even though we have many cases of patients who respond to targeted therapies because they have a mutation that's really significant, what we call a driver mutation, there are many other mutations that go along that can also contribute to resistance to a certain treatment.